Wedbush Maintains Outperform on Longboard Pharmaceuticals, Lowers Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico maintains an Outperform rating on Longboard Pharmaceuticals (NASDAQ:LBPH) but lowers the price target from $42 to $40.
August 02, 2024 | 1:19 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Wedbush analyst Laura Chico maintains an Outperform rating on Longboard Pharmaceuticals but lowers the price target from $42 to $40.
The Outperform rating suggests a positive outlook, but the lowered price target indicates some tempered expectations. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100